Congratulations on this landmark endovascular stroke trial!
Compared to the recent IMS III trial which enrolled patients with NIHSS >=10 (later amended to include NIHSS 8-9 if baseline CTA or MRA showed ICA, M1 or basilar occlusion), MR CLEAN enrolled patients with a broader range of severity (NIHSS >=2). A critical inclusion criterion of MR CLEAN is the presence of proximal occlusion in the anterior circulation (ICA, M1, M2), which closely resembles real-life practice.
While IMS III aimed to capture patients with a high likelihood of proximal occlusion by focusing on high NIHSS scores, it did not require baseline vessel imaging (only 47% had baseline CTA) and 21% of treatment group did not have a retrievable thrombus on angiogram, likely diluting treatment effects.
How many patients in the study had NIHSS of 2-7 and how did treatment group do compared to control? An example would be a left M1 clot with moderate aphasia (NIHSS =2), with a large penumbra.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.